Replimune (REPL) Free Cash Flow (2017 - 2026)
Replimune (REPL) posted Free Cash Flow of -$56.2 million for Q1 2026, up 14.5% sequentially from -$65.8 million in Q4 2025, and down 4.94% YoY from -$59.2 million in Q1 2025.
Replimune (REPL) Free Cash Flow (2017 - 2026) Analysis & Trends
Replimune has reported Free Cash Flow for 10 years, with the latest figure at -$56.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 4.94% year-over-year to -$56.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$280.4 million (down 45.73% YoY) and the FY2026 annual result came in at -$280.4 million, down 45.73% from the prior year.
- Free Cash Flow advanced to -$56.2 million in Q1 2026 per REPL's latest filing, from -$65.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$21.8 million in Q1 2022 and troughed at -$79.8 million in Q2 2025.
- A 5-year average of -$47.9 million and a median of -$47.3 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow climbed 5.91% in 2024, then plunged 93.13% in 2025.
- Over 5 years, Free Cash Flow stood at -$29.1 million in 2022, then sank by 61.22% to -$47.0 million in 2023, then declined by 0.6% to -$47.3 million in 2024, then plunged by 39.16% to -$65.8 million in 2025, then climbed by 14.5% to -$56.2 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$56.2 million, -$65.8 million, and -$78.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | -56.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.24 Mn |
| Mar 31, 2026 | -56.24 Mn |
| Dec 31, 2025 | -65.78 Mn |
| Dec 31, 2025 | -65.78 Mn |
| Sep 30, 2025 | -78.65 Mn |
| Sep 30, 2025 | -78.65 Mn |
| Jun 30, 2025 | -79.76 Mn |
| Jun 30, 2025 | -79.76 Mn |
| Mar 31, 2025 | -53.59 Mn |
| Mar 31, 2025 | -53.59 Mn |
| Dec 31, 2024 | -47.27 Mn |
| Dec 31, 2024 | -47.27 Mn |
| Sep 30, 2024 | -40.72 Mn |
| Sep 30, 2024 | -40.72 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -51.83 Mn |
| Mar 31, 2024 | -51.83 Mn |
| Dec 31, 2023 | -46.99 Mn |
| Dec 31, 2023 | -46.99 Mn |